Starpharma VP Dr Malcolm McColl appointed CEO of Viralytics

16-Nov-2012 - Australia

Starpharma Vice President Dr Malcolm McColl has been appointed Chief Executive Officer of Viralytics Limited.

From 2010 Dr McColl was Vice-President of Business Development at Starpharma where he was responsible for completion of partnering transactions with global and regional companies. He initiated and had a lead role in the development of Starpharma’s in-house docetaxel oncology drug program.

Prior to returning home to Australia in 2010 Dr McColl spent three years based in the UK at NYSE-listed global healthcare company Hospira as Business Development Director for Europe, Middle East and Africa. In that time he led negotiations and due diligence for a significant number of licensing and acquisition transactions with a focus on oncology.

Prior to this role he was Director of Business Development for the Asia Pacific region at Hospira (previously Mayne Pharma) and also 13 years with CSL in roles in its Animal Health Division including four years based in the USA as Global Vice-President Business Development.

Dr McColl has a Bachelor of Veterinary Science degree with first class honours from the University of Melbourne and an MBA from the Melbourne Business School.

https://www.bionity.com/en/news/140514/starpharma-vp-dr-malcolm-mccoll-appointed-ceo-of-viralytics.html